摘要:
The present invention relates to the use of hydroxamic acid derivatives containing an amidobenzoic moiety for the preparation of anti-tumour medicaments.
摘要:
The present invention relates to oligopeptides derived from fragments of the C-reactive protein (hereinafter CRP), and to their use as immunomodulating agents, and in the therapy of cardiovascular and inflammatory diseases.
摘要:
The use of derivatives of hydroxamic acid having histone deacetylase enzyme-inhibiting activity for the preparation of anti-inflammatory medicaments is disclosed.
摘要:
Compounds of formula (I) are described: The compounds (I) inhibit TNFα production and may therefore be useful in the treatment of inflammation, of auto-immune diseases, and of pathological conditions which involve excessive production of that cytokine. The compounds (I) are also inhibitors of the histone deacetylase enzyme and may therefore be useful in tumorous diseases, alone or in association with other anti-tumour active ingredients.
摘要:
The use of derivatives of hydroxamic acid having histone deacetylase enzyme-inhibiting activity for the preparation of anti-inflammatory medicaments is disclosed.
摘要:
Complexes of paroxetine, as free base or salt, with a cyclodextrin or a cyclodextrin derivative having a molar ratio between paroxetine and cyclodextrin ranging from 1:0.25 to 1:20, suitable for use in liquid and solid pharmaceutical compositions for oral and parenteral administration.
摘要:
Herein disclosed is a method for treating patients affected by HIV comprising administering N-hydroxy-benzamide-based histone deacetylase inhibitors, such as: • diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxymethyl)-naphtalen-2-yl- methyl] -ammonium chloride; • 4-(2-(S)-benzoylamino-3-naphtalen-2-yl-propionylamino)-N-hydroxy- benzamide; and/or • benzo[l,3]dioxole-5-carboxylic acid [l(S)-(4-hydroxycarbamoyl- phenylcarbamoyl)-2-naphtalen-2-yl-ethyl]-amide. Such histone deacetylase inhibitors are administered in a dosage ranging from 50 to 200 mg/day, preferably from 100 to 200 mg/day, so as to obtain a blood concentration between 125 and 250 nM.